Novonesis refines its long-term profile, shares trade steadily on Nasdaq Copenhagen

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-24, 09:11.

Novonesis (DK0060336014) stands out on Wednesday with a profile shaped by industrial enzymes and microbial solutions. The Danish biotech group, whose B shares trade in Copenhagen alongside peers like Novo Nordisk in the OMX Copenhagen family, is increasingly positioned as a long-term play on sustainable biomanufacturing.

What recent data points show

Novonesis arose from the merger of Chr. Hansen and Novozymes, a transaction completed in early 2024 that created a specialist in biosolutions for food, agriculture and industrial applications, according to the company overview on its website. Company investor information The group reports combined annual revenue measured in the billions of Danish kroner, with a diversified customer base spanning more than 140 countries based on earlier figures from the legacy businesses.

Integration has focused on combining research pipelines and production assets from the legacy entities while maintaining established customer relationships in dairy cultures, enzymes and agricultural biologicals, as outlined in merger documentation and prior public statements from the two companies. Reuters background on the merger The resulting cost and revenue synergies are expected to unfold over several years, a typical pattern for large-scale industrial integrations in the sector.

Long-term strategy and positioning

Novonesis concentrates on biosolutions that can help reduce environmental footprints in sectors such as textiles, household care and bioenergy, a positioning that differentiates it from pharmaceutical-focused Danish peers like Novo Nordisk. MarketScreener sector comparison By offering enzymes that enable lower-temperature washing or more efficient ethanol production, the group directly links its growth prospects to decarbonization and resource efficiency trends.

Management aims to combine innovation in strains and fermentation processes with global manufacturing capacity, building on decades of expertise from both predecessor companies as reflected in their historical annual reports. Historical data on Chr. Hansen This gives Novonesis a defensible moat in specialized applications where enzyme performance is critical and switching suppliers is complex for customers.

The biosolutions business model

Novonesis generates revenue by supplying tailored enzyme and microbial solutions that improve efficiency or quality in customer processes, rather than selling finished consumer goods. Overview of Novonesis solutions A representative product area is laundry detergent enzymes, which enable effective cleaning at lower water temperatures, reducing energy use for households.

Where the stock trades today

The Novonesis B shares (DK0060336014) trade on the Nasdaq Copenhagen market under the symbol NZYM B, with recent indicative prices around the mid-50 euro equivalent according to German trading data from platforms such as finanzen100 as of 2026-06-24, 09:00 CET.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance.